Analysts Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Price Target at $41.83

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been assigned a consensus recommendation of “Moderate Buy” from the eleven research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $41.8333.

STOK has been the subject of several recent research reports. BTIG Research reiterated a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a research note on Monday, May 11th. Wall Street Zen cut shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Wolfe Research started coverage on shares of Stoke Therapeutics in a research note on Monday, February 23rd. They set an “outperform” rating and a $40.00 price objective for the company. Needham & Company LLC boosted their price objective on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Finally, Canaccord Genuity Group boosted their price objective on shares of Stoke Therapeutics from $36.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, March 20th.

Insider Activity at Stoke Therapeutics

In related news, insider Barry Ticho sold 1,795 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $30.58, for a total transaction of $54,891.10. Following the completion of the transaction, the insider owned 34,826 shares of the company’s stock, valued at approximately $1,064,979.08. The trade was a 4.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 1,457 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total transaction of $43,637.15. Following the transaction, the general counsel directly owned 18,086 shares of the company’s stock, valued at approximately $541,675.70. This represents a 7.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Several hedge funds have recently bought and sold shares of the company. Kestra Advisory Services LLC bought a new stake in Stoke Therapeutics during the fourth quarter valued at approximately $26,000. KBC Group NV bought a new stake in Stoke Therapeutics during the first quarter valued at approximately $36,000. Harbour Investments Inc. lifted its position in Stoke Therapeutics by 312.9% during the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after purchasing an additional 898 shares during the last quarter. Generali Investments Management Co LLC bought a new stake in Stoke Therapeutics during the third quarter valued at approximately $41,000. Finally, BNP Paribas Financial Markets lifted its position in Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after purchasing an additional 1,668 shares during the last quarter.

Stoke Therapeutics Price Performance

STOK opened at $31.00 on Monday. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of -11.03 and a beta of 1.17. The firm has a 50-day moving average price of $31.93 and a 200-day moving average price of $32.34. Stoke Therapeutics has a twelve month low of $11.17 and a twelve month high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.01. The firm had revenue of $6.23 million during the quarter, compared to the consensus estimate of $6.48 million. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. On average, sell-side analysts expect that Stoke Therapeutics will post -3.22 earnings per share for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.